Schedule 13D ownership disclosure

Corvus Pharmaceuticals Inc

Common Stock · CUSIP: 221015100

Event date: 2026-01-23

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Adams Street Partners, LLCReported CIK 0001193586

    Shares: 3,275,616.00 · Class: 3.9%

  • Adams Street 2011 Direct Fund LPReported CIK 0001507788

    Shares: 694,854.00 · Class: 0.8%

  • Adams Street 2012 Direct Fund LPReported CIK 0001537362

    Shares: 715,361.00 · Class: 0.9%

  • Adams Street 2013 Direct Fund LPReported CIK 0001564720

    Shares: 541,133.00 · Class: 0.6%

  • Adams Street 2014 Direct Fund LPReported CIK 0001594043

    Shares: 736,033.00 · Class: 0.9%

  • Adams Street 2015 Direct Venture/Growth Fund LPReported CIK 0001623365

    Shares: 69,864.00 · Class: 0.1%

  • Adams Street 2016 Direct Venture/Growth Fund LPReported CIK 0001653592

    Shares: 67,769.00 · Class: 0.1%

  • Adams Street 2017 Direct Venture/Growth Fund LPReported CIK 0001685559

    Shares: 87,668.00 · Class: 0.1%

  • Adams Street 2018 Direct Venture/Growth Fund LPReported CIK 0001720383

    Shares: 126,806.00 · Class: 0.2%

  • Adams Street Venture/Growth Fund VI LPReported CIK 0001623687

    Shares: 236,128.00 · Class: 0.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-26-010750
Form type
SCHEDULE 13D/A
Filer
ADAMS STREET PARTNERS LLC
CIK
CIK 1193586
Filed
Feb 05, 2026
Reporting period
Jan 23, 2026
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub